Browsing by Author "Korkmaz, Taner"

Now showing 1 - 5 of 5

Comparison of second line treatment outcomes between sensitive and refractory small cell lung cancer patients: A retrospective analysis
(Elsevier, 2012-09) Korkmaz, Taner; Seber, Selçuk; Sarı, Eyüp; Ustaalioğlu, Başak Oven; Kefeli, Umut; Balvan, Özlem; Gümuş, Mahmut; Yaşar, Nurgül; Turhal, Nazım Serdar; Canhoroz, Mustafa; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.
Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: A retrospective analysis
(Springer, 2013-07) Korkmaz, Taner; Seber, Selçuk; Kefeli, Umut; Sarı, Enes; Öven, Bala Başak; Yıldırım, Emre; Yaşar, Nurgül; Balvan, Özlem; Şener, Nur Dinç ; Yüksel, Sinemis; Güven, Aslıhan Mert; Polat, Özge; Yumuk, Perran Fulden; Gümüş, Mahmut; Turhal, Nazım Serdar; Canhoroz, Mustafa; Aydın, Dinçer; Kanat, Özkan; Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı.; CJW-6018-2022; CCE-1550-2022; CYM-0930-2022; 52663246200; 55438191100; 55881548500
Small cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment. Methods: We retrospectively assessed data of 120 SCLC patients who failed first-line treatment and received second-line treatment at three medical oncology centers. Results: Median age of group was 58. 82 % had an ECOG PS of 0-1 at the time of relapse. 39 % were at limited stage (LS) at the time of diagnosis. Patients who progressed more than 3 months after first-line therapy were categorized as having platinum-sensitive disease (PSD) (64 %). The number of patients who received platin-based combination treatment was 33 (27 %). The median OS time starting from the initiation of second-line treatment was 7 months. Multivariate analysis identified PS (p = 0.006), extent of disease at diagnosis (0.014) and PSD (0.001) as the independent prognostic factors for survival. Subgroup analyses of the patients with PSD indicated platin rechallenge yields higher progression-free survival, overall survival and overall response rate. Conclusion: Patients with good ECOG PS,who have PSD or initially presenting with LS, have a good prognosis and in patients with PSD, platinum-based therapy would be more appropriate.
Correlation of high FDG uptake in PET/CT with poor prognosis in metastatic gastric adenocarcinoma.
(Lippincott Williams & Wilkins, 2011-05-20) Korkmaz, Taner; Seber, S.; Bilici, Ahmet; Okutur, Kerem; Toptaş, Tayfun; Başaran, Gül Atalay; Dede, Fuat; Yumuk, Perran Fulden; Dane, Faysal; Kanitez, Metin; Kanat, Oe; Gümüş, Mahmut; Demir, Gökhan; Turhal, Nazım Serdar; Canhoroz, Mustafa; Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı.
Efficacy and safety of trastuzumab emtansine in her2 positive metastatic breast cancer: Real-world experience
(Taylor & Francis, 2021-06-05) Bahçeci, Aykut; Paydaş, Semra; Ak, Naziye; Ferhatoğlu, Ferhat; Saip, Pınar Mualla; Şeydaoğlu, Gülşah; Bilici, Mehmet; Şimşek, Melih; Tekin, Salim Başol; Çalıkuşu, Züleyha; Yavuz, Sinan; Şahin, Ahmet Bilgehan; Çubukcu, Erdem; Evrensel, Türkkan; Değirmencioğlu, Serkan; Demiray, Atike Gökçen; Yumuk, Perran Fulden; Alan, Özkan; Çıkman, Duygu İlke; Demirelli, Fuat Hulusi; Köstek, Osman; Gökyer, Ali; Doğan, Mutlu; Bal, Öznur; Çakar, Burcu; Gökmen, Erhan; Yamaç, Deniz; Korkmaz, Taner; Aliyev, Altay; Keskin, Özge; Urvay, Semiha; Buyukşimşek, Mahmut; Karadeniz, Cemile; Yıldız, Birol; Çınkır, Havva Yeşil; Demir, Hacer; Beypınar, İsmail; Karacin, Cengiz; Eser, Kadir; Baykara, Meltem; Kılıçkap, Saadettin; Okutur, Kerem; Bulut, Gülcan; Alkan, Ali; Arpacı, Erkan; Pilancı, Kezban Nur; Demir, Atakan; Işık, Deniz; Yıldırım, Nilgün; ŞAHİN, AHMET BİLGEHAN; ÇUBUKÇU, ERDEM; EVRENSEL, TÜRKKAN; 0000-0002-7846-0870 ; AAM-4927-2020; JGT-4101-2023 ; EXZ-0745-2022
Aim The aim of this study is to evaluate the efficacy and toxicity of trastuzumab emtansine (T-DM1) in cases with metastatic breast cancer (mBC) in different lines of treatment. Method Retrospective analysis of T-DM1 results of human epidermal growth factor receptor 2 (Her2) positive 414 cases with mBC from 31 centers in Turkey. Findings Except 2, all of the cases were female with a median age of 47. T-DM1 had been used as second-line therapy in 37.7% of the cases and the median number of T-DM1 cycles was 9. Progression-free survival (PFS) and overall survival (OS) times were different according to the line of treatment. The median OS was found as 43, 41, 46, 23 and 17 months for 1st, 2nd, 3rd, 4th and 5th line, respectively (p = 0.032) while the median PFS was found as 37, 12, 8, 8 and 8 months, respectively (p = 0.0001). Treatment was well tolerated by the patients. The most common grade 3-4 adverse effects were thrombocytopenia (2.7%) and increased serum gamma-glutamyl transferase (2%). Discussion The best of our knowledge this is the largest real-life experience about the safety and efficacy of T-DM1 use in cases with mBC after progression of Her2 targeted treatment. This study suggests and supports that T-DM1 is more effective in earlier lines of treatment and is a reliable option for mBC.
Primary small cell carcinoma of the breast: Report of seven cases and review of the literature
(Sage Publications, 2011-07) Kılıçkap, Saadetin; Korkmaz, Taner; Öven, Bala Başak Ustaalıoğlu; Kanat, Özkan; Canhoroz, Mustafa; Çubukçu, Erdem; Tolunay, Şahsine; Evrensel, Türkkan; Manavoğlu, Osman; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; 0000-0002-9732-5340; AAI-1612-2021; AAJ-1027-2021; 55881548500; 52663246200; 53986153800; 6602604390; 6603942124; 6602587152
Aims and background. The aim of the study was to analyze the clinicopathological characteristics, treatment modalities, and clinical outcome of patients with primary small cell carcinoma of the breast. Methods. Fifty-three cases of primary small cell carcinoma of the breast were identified; 7 cases in this series and 46 from the English-language medical literature. Results. There were 52 females and 1 male. The mean age was 53 years. Tumor size ranged from 1 to 18 cm (mean, 4.53). Axillary node metastasis was present in 61.7%. Only one patient had distant metastases at presentation. The presence of hormone receptors was reported in 24.5% of the tumors. Modified radical mastectomy was the most common surgical procedure and was performed in 50.9% of the patients. Adjuvant radiotherapy was administered to 39.6% of the patients, and 69.8% underwent chemotherapy. Thirteen percent of patients received adjuvant tamoxifen therapy. The mean follow-up was 20.75 months (range, 3-60), and 10 of 53 cases (18.9%) died of metastatic disease. Conclusions. The prognosis of primary small cell carcinoma of the breast largely depends on the initial stage of the disease. Multimodality treatment including surgery, radiotherapy and chemotherapy seems to be the most appropriate strategy for early disease. Chemotherapy is usually unsuccessful in treating metastatic disease.